Non-Incretin Pathways: Novel Mechanisms of Action Research is exploring pathways independent of the traditional incretin system to address limitations like side effects and weight plateaus
What's New with GLP-1 Coverage in 2026 While GLP-1 agonists have been around for over a decade now, they've seen a big jump in popularity in the last couple of years
Customers and institutional purchasers must comply with all applicable purchase, importation, possession, and use requirements in their jurisdiction
OAs potentially perform multiple functions in the rhizosphere
However, it should be carefully noted that the very limited number of human trials have made no specific mention of adverse reactions
Such consolidated cases often last 4-5 years, said Elizabeth Chamblee Burch, a University of Georgia law professor who is an expert in multidistrict litigation